With regards to type 2 diabetes mellitus, Gault et al67 initially indicated that a GLP-1 and GIP preparation, that combinedlong-acting acylated version of the parent peptides, displayed enhancedglucose-lowering and insulinotropic actions in animal models of diabetes. Here, GIP is linked to type 2 diabetes mellitus.